ID   VH-64
AC   CVCL_9672
SY   VH 64; VH64
DR   EFO; EFO_0002870
DR   cancercelllines; CVCL_9672
DR   GEO; GSM510015
DR   IARC_TP53; 23653
DR   Progenetix; CVCL_9672
DR   Wikidata; Q54993098
RX   PubMed=1320624;
RX   PubMed=8335680;
RX   PubMed=8378080;
RX   PubMed=15150091;
RX   PubMed=19787792;
RX   PubMed=21822310;
RX   PubMed=26428435;
RX   PubMed=30879952;
CC   From: Van Valen F.; University of Munster; Munster; Germany.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=15150091).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=19787792; PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 12
ST   D18S51: 13,14
ST   D19S433: 12,15
ST   D21S11: 30.2,31
ST   D2S1338: 19,24
ST   D3S1358: 16,17
ST   D5S818: 12,13
ST   D7S820: 12
ST   D8S1179: 14
ST   FGA: 22,23 (PubMed=30879952)
ST   FGA: 23 (PubMed=19787792)
ST   SE33: 16,23
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 15,19
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=1320624; DOI=10.1007/BF01225268;
RA   van Valen F., Winkelmann W., Jurgens H.;
RT   "Expression of functional Y1 receptors for neuropeptide Y in human
RT   Ewing's sarcoma cell lines.";
RL   J. Cancer Res. Clin. Oncol. 118:529-536(1992).
//
RX   PubMed=8335680; DOI=10.1007/BF01372725;
RA   van Valen F., Winkelmann W., Burdach S., Gobel U., Jurgens H.;
RT   "Interferon gamma and tumour necrosis factor alpha induce a
RT   synergistic antiproliferative response in human Ewing's sarcoma cells
RT   in vitro.";
RL   J. Cancer Res. Clin. Oncol. 119:615-621(1993).
//
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//